148,256 Shares in Neogen Corporation $NEOG Purchased by Grandeur Peak Global Advisors LLC

Grandeur Peak Global Advisors LLC purchased a new stake in Neogen Corporation (NASDAQ:NEOG) during the 2nd quarter, HoldingsChannel reports. The fund purchased 148,256 shares of the company’s stock, valued at approximately $1,333,000.

A number of other large investors have also recently modified their holdings of NEOG. Public Employees Retirement System of Ohio purchased a new position in shares of Neogen during the second quarter worth about $34,000. UMB Bank n.a. increased its position in shares of Neogen by 238.2% in the fourth quarter. UMB Bank n.a. now owns 6,422 shares of the company’s stock worth $45,000 after purchasing an additional 4,523 shares during the last quarter. Hantz Financial Services Inc. raised its stake in Neogen by 816.9% in the fourth quarter. Hantz Financial Services Inc. now owns 7,592 shares of the company’s stock valued at $53,000 after purchasing an additional 6,764 shares in the last quarter. Cresset Asset Management LLC bought a new stake in Neogen during the second quarter valued at approximately $53,000. Finally, Evergreen Capital Management LLC purchased a new position in Neogen in the 2nd quarter worth approximately $56,000. Institutional investors own 96.73% of the company’s stock.

Key Headlines Impacting Neogen

Here are the key news stories impacting Neogen this week:

• Positive Sentiment: Piper Sandler upgraded Neogen on new management, suggesting analysts see potential for improved execution and a stronger outlook under the company’s leadership changes. Neogen upgraded at Piper Sandler on new management
• Positive Sentiment: Zacks Research raised several Neogen EPS forecasts: FY2027 estimates increased to $0.25 from $0.21, FY2028 to $0.29 from $0.28, and FY2029 was projected at $0.32. Quarterly estimates for Q2 and Q3 FY2027, Q4 FY2027 and Q3–Q4 FY2028 were also raised, signaling expectations for gradual earnings improvement. These forecasts are broadly in line with or above the current-year consensus of $0.25 EPS.
• Neutral Sentiment: Signal Proxy Intelligence recommended shareholders support all five proposals at Neogen’s annual meeting. The endorsement may reduce governance uncertainty, but it is unlikely to materially change near-term earnings or valuation. Signal Proxy Intelligence Recommends Full Support for All Five Items at Neogen Corporation Annual Meeting
• Neutral Sentiment: A Zacks comparison of Perrigo and Neogen framed the stocks as competing medical-products value investments. The article does not represent a specific change to Neogen’s rating or outlook. PRGO or NEOG: Which Is the Better Value Stock Right Now?
• Negative Sentiment: Zacks lowered its Q1 FY2028 EPS forecast to $0.05 from $0.06, partially offsetting the broader upward revisions. The change suggests some unevenness in the pace of Neogen’s expected earnings recovery.

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. Piper Sandler raised shares of Neogen from a “neutral” rating to an “overweight” rating and lifted their price objective for the stock from $13.00 to $14.00 in a report on Wednesday. Weiss Ratings upgraded Neogen from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, August 7th. Finally, Wall Street Zen raised Neogen from a “hold” rating to a “buy” rating in a research note on Saturday, May 9th. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $12.00.

Neogen Price Performance

NEOG opened at $11.74 on Friday. The stock’s 50 day simple moving average is $10.42 and its 200 day simple moving average is $9.85. The company has a debt-to-equity ratio of 0.38, a current ratio of 3.82 and a quick ratio of 2.91. Neogen Corporation has a 1 year low of $4.90 and a 1 year high of $12.85. The firm has a market cap of $2.56 billion, a price-to-earnings ratio of -391.33, a PEG ratio of 4.39 and a beta of 1.77.

Neogen (NASDAQ:NEOG) last released its quarterly earnings data on Thursday, July 30th. The company reported $0.09 earnings per share for the quarter, beating analysts’ consensus estimates of $0.06 by $0.03. The firm had revenue of $225.30 million during the quarter, compared to analyst estimates of $212.35 million. Neogen had a positive return on equity of 2.78% and a negative net margin of 0.91%.The business’s quarterly revenue was down .1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($2.82) earnings per share. As a group, analysts predict that Neogen Corporation will post 0.27 earnings per share for the current year.

Neogen Company Profile

Neogen Corporation is a global provider of food and animal safety products, offering a broad portfolio of diagnostic and testing solutions. Headquartered in Lansing, Michigan, the company develops and manufactures tests designed to detect foodborne pathogens, allergens and toxins in food, beverage and environmental samples. Since its founding in 1982, Neogen has focused on delivering rapid, accurate and user‐friendly assays to food processors, grain handlers and quality laboratories around the world.

In the food safety arena, Neogen’s product lineup includes immunoassay kits, molecular diagnostics and enrichment media for pathogens such as Salmonella, Listeria and E.